Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
1.
Reumatol. clín. (Barc.) ; 12(4): 226-227, jul.-ago. 2016. tab
Article in Spanish | IBECS | ID: ibc-153629

ABSTRACT

La fiebre chikungunya es una infección viral, transmitida por mosquitos, que cursa con fiebre, rash y síntomas musculoesqueléticos que pueden persistir meses, incluso años, de una forma crónica o recidivante precisando adecuado tratamiento. La extensa epidemia declarada en el Caribe en 2013ha provocado el aumento de los casos importados en los países no endémicos, así como del riesgo de transmisión autóctona en aquellas zonas donde se encuentran vectores, como es el caso de España. Describimos 4 casos de chikungunya atendidos en nuestras consultas (AU)


Chikungunya Fever is a mosquito-transmitted viral disease that causes fever, rash and musculoskeletal complaints. The latest may persist for several months, or even years or developed a relapsing course, that deserve an adequate treatment. Due to the large outbreak declared in the Caribbean in 2013, imported cases of Chikungunya as well as the risk of autochthonous transmission in case of available vectors have increased in non-endemic countries, like Spain. We described four cases of Chikungunya treated in our clinic (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Chikungunya virus/isolation & purification , Chikungunya Fever/blood , Chikungunya Fever/complications , Chikungunya Fever/drug therapy , Arthralgia/complications , Arthralgia/drug therapy , Arthritis/complications , Arthritis/drug therapy , Exanthema/complications , Prednisone/therapeutic use , Primary Health Care/methods , Fever/complications , Fever/drug therapy , Fever/etiology , Immunoglobulin M/analysis , Arthritis/blood , Arthritis/diagnosis , Immunologic Factors/analysis , Diagnosis, Differential
2.
Reumatol Clin ; 12(4): 226-7, 2016.
Article in English, Spanish | MEDLINE | ID: mdl-26374958

ABSTRACT

Chikungunya Fever is a mosquito-transmitted viral disease that causes fever, rash and musculoskeletal complaints. The latest may persist for several months, or even years or developed a relapsing course, that deserve an adequate treatment. Due to the large outbreak declared in the Caribbean in 2013, imported cases of Chikungunya as well as the risk of autochthonous transmission in case of available vectors have increased in non-endemic countries, like Spain. We described four cases of Chikungunya treated in our clinic.


Subject(s)
Chikungunya Fever/diagnosis , Travel , Adult , Chikungunya Fever/transmission , Diagnosis, Differential , Dominican Republic , Female , Humans , Male , Middle Aged , Spain
3.
Reumatol. clín. (Barc.) ; 7(5): 284-298, sept.-oct. 2011. tab
Article in Spanish | IBECS | ID: ibc-90946

ABSTRACT

Objetivo: Dado el creciente uso de las terapias biológicas en distintas enfermedades reumatológicas, y la importancia de la gestión de riesgo de las mismas, desde la Sociedad Española de Reumatología (SER) se ha impulsado el desarrollo de recomendaciones basadas en la mejor evidencia posible. Estas deben de servir de referencia para reumatólogos e implicados en el tratamiento de pacientes en tratamiento o en los que se quiere indicar la terapia biológica independientemente de su enfermedad de base. Métodos: Las recomendaciones se emitieron siguiendo la metodología de grupos nominales. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford y el grado de acuerdo se extrajo por técnica Delphi. Se utilizó toda la información de consensos y guías de práctica clínica previas. Resultados: Se realizan recomendaciones sobre la gestión del riesgo del uso de las terapias biológicas en pacientes con enfermedades reumática. Incluyen la gestión del riesgo de la indicación, gestión del riesgo antes de iniciar el tratamiento, gestión del riesgo durante el seguimiento, actitud ante acontecimientos adversos, y actitud en situaciones especiales. Conclusiones: Se presentan las recomendaciones SER sobre la gestión del riesgo del tratamiento con terapias biológicas (AU)


Objective: Due to the increasing use of biologic therapy in rheumatic diseases and the importance of its risk management, the Spanish Society of Rheumatology (SER) has promoted the development of recommendations based on the best evidence available. These recommendations should be a reference to rheumatologists and those involved in the treatment of patients who are using, or about to use biologic therapy irrespectively of the rheumatic disease. Methods: Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and degree of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through a Delphi technique. Evidence from previous consensus and clinical guidelines was used. Results: We have produced recommendations on risk management of biologic therapy in rheumatic patients. These recommendations include indication risk management, risk management before the use of biologic therapy, risk management during follow-up, attitude to adverse events, and attitude to special situations. Conclusions: We present the SER recommendations related to biologic therapy risk management (AU)


Subject(s)
Humans , Male , Female , Biological Therapy/methods , Biological Therapy/trends , Rheumatic Diseases/therapy , Autoimmune Diseases/complications , Autoimmune Diseases/therapy , Biological Therapy/classification , Biological Therapy/instrumentation , Biological Therapy , Risk Factors
4.
Reumatol Clin ; 7(5): 284-98, 2011.
Article in Spanish | MEDLINE | ID: mdl-21925444

ABSTRACT

OBJECTIVE: Due to the increasing use of biologic therapy in rheumatic diseases and the importance of its risk management, the Spanish Society of Rheumatology (SER) has promoted the development of recommendations based on the best evidence available. These recommendations should be a reference to rheumatologists and those involved in the treatment of patients who are using, or about to use biologic therapy irrespectively of the rheumatic disease. METHODS: Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and degree of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through a Delphi technique. Evidence from previous consensus and clinical guidelines was used. RESULTS: We have produced recommendations on risk management of biologic therapy in rheumatic patients. These recommendations include indication risk management, risk management before the use of biologic therapy, risk management during follow-up, attitude to adverse events, and attitude to special situations. CONCLUSIONS: We present the SER recommendations related to biologic therapy risk management.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antirheumatic Agents/therapeutic use , Biological Therapy , Immunosuppressive Agents/therapeutic use , Rheumatic Diseases/drug therapy , Anti-Inflammatory Agents/adverse effects , Antirheumatic Agents/adverse effects , Delphi Technique , Humans , Immunosuppressive Agents/adverse effects , Pharmacovigilance , Risk Management
SELECTION OF CITATIONS
SEARCH DETAIL
...